Generate Biomedicines Bolsters Leadership Team with the Addition of Jason Silvers, M.D., J.D., as Chief Financial Officer

For­mer Gold­man Sachs Co-head of EMEA Health­care Invest­ment Bank­ing, Part­ner and Man­ag­ing Direc­tor brings exten­sive expe­ri­ence in cor­po­rate biotech and strate­gic finance

Somerville, Mass, July 25, 2022 – Gen­er­ate Bio­med­i­cines, whose machine learn­ing-pow­ered gen­er­a­tive biol­o­gy plat­form can rapid­ly invent new drugs across a wide range of pro­tein modal­i­ties and pre­vi­ous­ly undis­cov­er­able pro­tein ther­a­peu­tics, today announced that Jason Sil­vers, M.D., J.D., has been named the company’s Chief Finan­cial Offi­cer, over­see­ing all finan­cial mat­ters as the com­pa­ny advances into its next stage of growth. 

Dr. Sil­vers was at Gold­man Sachs for 20 years, where he was named man­ag­ing direc­tor in 2010 and Part­ner in 2014. Most recent­ly, he was based in Lon­don and co-man­aged health­care invest­ment bank­ing for Europe, the Mid­dle East and Africa. Pre­vi­ous­ly, he served as the Glob­al Head of Health­care Merg­ers & Acqui­si­tions. Over his career, he has com­plet­ed more than 75 merg­er and acqui­si­tion and financ­ing trans­ac­tions val­ued at more than $400 billion.

We’re thrilled that Jason is join­ing the Gen­er­ate Bio­med­i­cines team at this excit­ing time in Generate’s devel­op­ment pio­neer­ing gen­er­a­tive biol­o­gy,” said Mike Nal­ly, Generate’s Chief Exec­u­tive Offi­cer. His stel­lar back­ground, breadth and depth of exper­tise, includ­ing his strate­gic and trans­ac­tion­al expe­ri­ence, are invalu­able attrib­ut­es that will help fuel our growth as we grow our orga­ni­za­tion to sup­port our ambi­tious busi­ness objectives.”

Dr. Sil­vers com­ment­ed, Gen­er­ate is rev­o­lu­tion­iz­ing drug devel­op­ment through a pow­er­ful new approach to mak­ing pro­tein ther­a­peu­tics. With $370 mil­lion in Series B fund­ing, a part­ner­ship with Amgen, and the extra­or­di­nary poten­tial of its tech­nol­o­gy plat­form, the com­pa­ny is well-posi­tioned to make his­to­ry. I am excit­ed to work close­ly with such a tal­ent­ed team to help advance the company’s com­put­er-gen­er­at­ed pro­tein therapeutics.”

He grad­u­at­ed magna cum laude from Brown Uni­ver­si­ty with a bachelor’s of sci­ence degree in chem­istry. He attend­ed the Johns Hop­kins Uni­ver­si­ty School of Med­i­cine. After med­ical school, he com­plet­ed one year of a neu­ro­sur­gi­cal res­i­den­cy at Jack­son Memo­r­i­al Hos­pi­tal and was award­ed the Sur­gi­cal Intern of the Year dis­tinc­tion. He con­tin­ued his edu­ca­tion at Yale Law School, where he earned his juris doc­tor degree and was edi­tor-in-chief of the Yale Jour­nal of Health Pol­i­cy, Law, and Ethics.

About Gen­er­a­tive Biology

Gen­er­a­tive biol­o­gy rep­re­sents a fun­da­men­tal shift in ther­a­peu­tic devel­op­ment that is dri­ven by machine intel­li­gence. This new approach leaves tra­di­tion­al tri­al and error meth­ods of drug dis­cov­ery behind and is ush­er­ing in a new era of pro­gram­ma­ble drug engi­neer­ing. Rather than dis­cov­er­ing” what’s observ­able in the lab, Gen­er­ate Bio­med­i­cines is cre­at­ing ther­a­peu­tic oppor­tu­ni­ties by iden­ti­fy­ing spe­cif­ic bio­log­i­cal process­es involved in dis­ease that can be mod­u­lat­ed with a wide range of pro­tein modal­i­ties. The promise of gen­er­a­tive biol­o­gy goes beyond exist­ing pro­teins found in nature and can gen­er­ate entire­ly nov­el, de novo pro­teins that are pur­pose-built to address an exist­ing or emerg­ing ther­a­peu­tic need. Gen­er­a­tive biol­o­gy will enable ther­a­peu­tic achieve­ments nev­er before pos­si­ble, cre­at­ing entire­ly new ways to treat all types of dis­eases, dras­ti­cal­ly increas­ing the suc­cess rate, and reduc­ing the time required for drug discovery.

About Gen­er­ate Biomedicines 

Gen­er­ate Bio­med­i­cines is the first drug gen­er­a­tion com­pa­ny, pio­neer­ing a machine learn­ing-pow­ered mul­ti­modal­i­ty gen­er­a­tive biol­o­gy plat­form with the abil­i­ty to gen­er­ate new drugs on demand across a wide range of bio­log­ic modal­i­ties. Through the seam­less inte­gra­tion of com­pu­ta­tion­al and wet lab capa­bil­i­ties, Generate’s plat­form can dras­ti­cal­ly improve the speed at which tar­gets and ther­a­peu­tics are iden­ti­fied and val­i­dat­ed, the speci­fici­ty of tar­get engage­ment by gen­er­at­ed pro­teins, and the cost of iden­ti­fy­ing and devel­op­ing clin­i­cal can­di­dates. The company’s plat­form rep­re­sents a poten­tial­ly fun­da­men­tal shift in what’s pos­si­ble in the field of ther­a­peu­tic devel­op­ment, address­ing key chal­lenges of drug dis­cov­ery and dras­ti­cal­ly expand­ing the avail­able search space for nov­el bio­med­i­cines. Gen­er­ate Bio­med­i­cines was found­ed by Flag­ship Pio­neer­ing after two years of foun­da­tion­al research in its Labs unit and launched in 2020. Learn more about Gen­er­ate Bio­med­i­cines by vis­it­ing https://​gen​er​ate​bio​med​i​cines​.com/ or fol­low­ing the com­pa­ny on Twit­ter and LinkedIn.

Gen­er­ate Media Con­tact:
Court­ney Heath